BIIB Q1 2025 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.4B+6.1% YoY

Gross Profit

$1.9B76.2% margin

Operating Income

$733M30.1% margin

Net Income

$241M9.9% margin

EPS (Diluted)

$1.64

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

$259M

Free Cash Flow

$212M

Stock-Based Comp.

$81M

Balance Sheet

Total Assets

$28.0B

Total Liabilities

$11.1B

Stockholders' Equity

$17.0B

Cash & Equivalents

$2.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.3B	+6.1%
Gross Profit	$1.9B	$1.8B	+3.4%
Operating Income	$733M	$690M	+6.1%
Net Income	$241M	$393M	-38.9%

Revenue Segments

MS Product Revenues

$953M41%

SPINRAZA

$424M18%

TYSABRI product

$382M16%

Fumarate

$345M15%

Interferon

$226M10%

Geographic Segments

Non-US

$973M56%

UNITED STATES

$754M44%